Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Loren Walensky
Harvard Medical School, Department: Biology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Aileron Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Aileron Therapeutics has licensed the peptide stapling technology from DFCI and is currently working to commercialize the stapled peptides the company designs, which are unrelated to this funded research, for clinical use. Dr. Pritz and Dr. Walensky will be using the technology in the research to make and work on new and independent compounds entirely unrelated to Aileron Therapeutics’ stapled peptides. The grant does not employ any reagents from Aileron Therapeutics and no unpublished information that derives from the funded research is shared with Aileron Therapeutics. Further, Dr. Walensky does not conduct sponsored research for Aileron Therapeutics or any other entity. Because Dr. Walensky owns equity in an entity whose financial interest could be affected by the design, conduct, or reporting of work pursuant to the NIH-funded research, HMS has determined that the ownership of equity ((b)(4)) constitutes a potential financial conflict of interest.
Dissecting the Functional Roles of Two BH3-Binding Sites on Pro-Apoptotic BAX
BAX is a pro-apoptotic BCL-2 family member that, in response to cellular stress, transforms from an inactive cytosolic monomer into a toxic mitochondrial pore, a mechanism effectively suppressed by cancer cells to ensure their immortality. The Walensky laboratory recently identified two 'trigger sites' at BAX's N- and C-terminal surfaces that are believed to initiate and propel the BAX activation mechanism. Using multidisciplinary approaches, I am to dissect the binding determinants of these distinct regulatory sites and determine how specific ligand interaction impacts the BAX activation process, with the ultimate goal of advancing a new therapeutic strategy for reactivating the death pathway in cancer through direct BAX interaction.
Filed on October 22, 2014.
Tell us what you know about Loren Walensky's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Loren Walensky”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Loren Walensky | Dana Farber Cancer Inst | Conflict of Interest | Aileron Therapeutics | Value cannot be readily determined |
| Loren Walensky | Harvard Medical School | Conflict of Interest | Aileron Therapeutics | $100,000 - $149,999 |
| Loren Walensky | Dana Farber Cancer Inst | Conflict of Interest | Aileron Therapeutics | $150,000 - $199,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.